Bromodeoxyuridine-induced expression of endothelin A in A375 human melanoma cells

Expression of endothelin (ET) receptor subtypes was examined in an experimental model of A375 human melanoma cell differentiation using the pyrimidine analog bromodeoxyuridine (BUdR). BUdR (10 microM)-treated cells had an increased surface area and an increased dendricity, were contact-inhibited and lacked tumorigenecity in athymic nude mice. The untreated A375 cells exclusively expressed ETB and BUdR-induced phenotypical changes were accompanied by induction of ETA expression as evidenced by northern blotting, [125I]ET-1 binding assay and [Ca2+]i measurement. Thus, BUdR-induced differentiation of A375 melanoma cells may provide a model system to study the receptor subtype switch in melanocyte development.